본문으로 건너뛰기
← 뒤로

Tobacco-related urinary biomarkers and lung cancer risk in women, a case-cohort analysis.

1/5 보강
Journal of the National Cancer Institute 📖 저널 OA 39.2% 2023: 3/4 OA 2024: 6/8 OA 2025: 30/56 OA 2026: 33/113 OA 2023~2026 2026
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
356 cases and 433 non-cases.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In women who did not smoke, positive associations were observed for styrene/ethylbenzene and dimethylformamide/methylisocyanate biomarkers. [CONCLUSION] Exposure to PAHs, TSNAs and several VOCs through tobacco smoking were associated with increased lung cancer risk among women.

Nalini M, O'Brien KM, Calafat AM, Wang L, Feng J, Reese CM, Xia B, Botelho JC, Wang Y, Seyler T, Roh EJ, Tashakkori NA, Blakney A, Xu K, Gail MH, Blount BC, Chang CM, Abnet CC, Sandler DP, Freedman ND, Etemadi A

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

[BACKGROUND] The constituents of tobacco smoke that specifically contribute to lung cancer risk have yet to be fully identified.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 추적기간 9.6 years
  • 연구 설계 cohort study

이 논문을 인용하기

↓ .bib ↓ .ris
APA Nalini M, O'Brien KM, et al. (2026). Tobacco-related urinary biomarkers and lung cancer risk in women, a case-cohort analysis.. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djag078
MLA Nalini M, et al.. "Tobacco-related urinary biomarkers and lung cancer risk in women, a case-cohort analysis.." Journal of the National Cancer Institute, 2026.
PMID 41849411 ↗

Abstract

[BACKGROUND] The constituents of tobacco smoke that specifically contribute to lung cancer risk have yet to be fully identified. We evaluated associations between biomarkers of potentially harmful constituents-polycyclic aromatic hydrocarbons (PAHs), tobacco-specific nitrosamines (TSNAs), nicotine, and volatile organic compounds (VOCs)-and lung cancer incidence among US women.

[METHODS] In a case-cohort study nested within the Sister Study (women aged 35 to 74 years at baseline, enrolled 2003 to 2009), data were obtained for a random subcohort and all remaining incident lung cancers through September 2017 (median follow-up 9.6 years), stratified by race and ethnicity (Hispanic, non-Hispanic Black, non-Hispanic White, others) and smoking status (current, former, never). The analytic sample included 356 cases and 433 non-cases. We quantified 30 biomarkers in baseline urine samples and calculated hazard ratios (HRs) for associations between one-unit increase in biomarker concentrations (log-scale) and lung cancer incidence using weighted Cox regression models adjusted for urinary creatinine and demographic, health, and lifestyle factors.

[RESULTS] Among women who were currently smoking at enrolment, positive associations were observed for biomarkers of PAHs (naphthalene, phenanthrene, pyrene, fluorene; HRs 1.4 to 5.3), TSNAs (particularly 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK); HRs : 1.3-2.2), and VOCs (xylene, acrylamide, acrylonitrile, 1,2-dibromoethane/vinyl-chloride/ethylene-oxide/acrylonitrile, acrolein, styrene/ethylbenzene, benzene, dimethylformamide/methylisocyanate, 1,3-butadiene, crotonaldehyde, isoprene; HRs : 1.6-4.4). Associations with biomarkers of most PAHs, NNK, xylene, and dimethylformamide/methylisocyanate remained after additional adjustment for smoking frequency, duration, and nicotine metabolites. In women who did not smoke, positive associations were observed for styrene/ethylbenzene and dimethylformamide/methylisocyanate biomarkers.

[CONCLUSION] Exposure to PAHs, TSNAs and several VOCs through tobacco smoking were associated with increased lung cancer risk among women.